Vaccitech, a biotech startup company that contributed to COVID-19 vaccine research, is launching its IPO in the NASDAQ on April 29. All the funds raised with the IPO will be likely invested into drugs against hepatitis B virus, human papilloma virus, and prostate cancer.

Vaccitech took part in developing AstraZeneca vaccine, which is recommended by the World Health Organization.

In March 2020, Vaccitech raised $168M over an investment round, some of the investors being M&G Investment Management, Tencent, Gilead Sciences, Future Planet Capital, and Oxford Sciences Innovation. The officials at the Oxford University are expecting this IPO to be the best start in the scientific R&D domain over the last few years.

Analysts at various investment banks believe the COVID vaccine market may exceed $10 B per year, based on the number of people who take seasonal flu vaccines every year. In case the vaccine gets even more popular, the market size may reach $25B per year.

Vaccitech IPO: Key Facts

You can find Vaccitech Security Issue Memo on the SEC website.

You can apply to trade Vaccitech IPO before 7:00 pm UTC+2 on April 28. In order to trade on an IPO, you need an investment account with Freedom Finance. The minimum investment amount is $2,000.

As there is a huge number of people willing to invest into IPO's, you may receive shares worth a smaller amount than you specified in your order. Learn how to increase your allocation and get more IPO shares here.